{"id":23070,"date":"2026-03-02T15:34:09","date_gmt":"2026-03-02T15:34:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/23070\/"},"modified":"2026-03-02T15:34:09","modified_gmt":"2026-03-02T15:34:09","slug":"emcure-in-pact-with-roche-to-distribute-select-nephrology-and-transplant-medicines","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/23070\/","title":{"rendered":"Emcure in pact with Roche to distribute select nephrology and transplant medicines"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/1x1_spacer.png\" alt=\"It will also distribute Mircera and Neorecormon \u2013 proven therapies for anemia in chronic kidney disease, including Mircera\u2019s long-acting product with dosing once every 2\u20134 weeks.\" title=\"It will also distribute Mircera and Neorecormon \u2013 proven therapies for anemia in chronic kidney disease, including Mircera\u2019s long-acting product with dosing once every 2\u20134 weeks.\" data-original=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/1x1_spacer.png\" class=\"article-pictue\"\/><\/p>\n<p class=\"caption\">\n\t\t\t\t\t\t\t\t\t\tIt will also distribute Mircera and Neorecormon \u2013 proven therapies for anemia in chronic kidney disease, including Mircera\u2019s long-acting product with dosing once every 2\u20134 weeks.\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/p>\n<p>Emcure Pharmaceuticals has inked a distribution pact with Roche for select products in the nephrology and transplant medicine portfolio, effective April 1.<\/p>\n<p>The agreement would help expand access to therapies in chronic kidney disease (CKD), anemia management, and transplant care across India, the companies said in a joint communication.<\/p>\n<p>Emcure will distribute Roche\u2019s CellCept, an immunosuppressant and original Roche innovation supporting organ transplants worldwide since 1995, the companies said. It will also distribute Mircera and Neorecormon \u2013 proven therapies for anemia in chronic kidney disease, including Mircera\u2019s long-acting product with dosing once every 2\u20134 weeks.<\/p>\n<p>Emcure is a market leader in anemia management, and together with its subsidiaries, has a presence across nephrology and chronic kidney disease segments. Roche\u2019s nephrology and transplant portfolio complements Emcure\u2019s offerings, the note said.<\/p>\n<p>Satish Mehta, Emcure Managing Director and Chief Executive said, the companies would together expand access to these critical therapies and support physicians in delivering care to patients across India. Rajji Mehdwan, Managing Director &amp; CEO, Roche India &amp; Neighbouring Markets, said, \u201cThrough Emcure\u2019s strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche\u2019s long-standing innovations in transplant and CKD care.\u201d<\/p>\n<p class=\"publish-time\" id=\"end-of-article\">Published on  March 2, 2026 <\/p>\n","protected":false},"excerpt":{"rendered":"It will also distribute Mircera and Neorecormon \u2013 proven therapies for anemia in chronic kidney disease, including Mircera\u2019s&hellip;\n","protected":false},"author":2,"featured_media":23071,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2370,14828,134],"class_list":["post-23070","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-companies","tag-emcure","tag-roche"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=23070"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23070\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/23071"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=23070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=23070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=23070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}